Ronald Drengler, MD

home / authors / ronald-drengler-md

Articles

Docetaxel in Combination With Flourouracil: Study Design and Preliminary Results

Eric Rowinsky, MD;Lon Smith, MD;Gladys Rodriguez, MD;Ronald Drengler, MD;Daniel D. Von Hoff, MD;Nancy Peacock, MD;Cheryl Aylesworth, MD;Howard A. Burris III, MD;Peter Ravdin, MD, PhD;Robert Bellet, MD

June 1st 1997

The relatively recent introduction of a new class of chemotherapeutic agents--the taxoids--has raised hope of improved survival for patients with advanced or metastatic cancer. Following encouraging preclinical results of taxoid combinations, this phase I, nonrandomized trial was designed to evaluate a 1-hour intravenous infusion of docetaxel (Taxotere) on day 1 combined with fluorouracil (5-FU) as a daily intravenous bolus for 5 consecutive days.

New Anticancer Agents in Clinical Development

John Eckardt, MD;S. Gail Eckhardt, MD;Miguel A. Villalona-calero, MD;Ronald Drengler, MD

November 1st 1995

A better understanding of the biology and biochemistry of the cancer cell has led to the development of various promising new antineoplastic compounds that are now undergoing phase I, II, and III clinical testing. These drugs include topoisomerase I inhibitors, such as camptothecin and its analogs 9-aminocamptothecin, irinotecan, and topotecan; the paclitaxel analog docetaxel; gemcitabine, an antimetabolite structurally related to cytarabine; and fluorouracil prodrugs and other thymidylate synthase (TS) inhibitors.